The analysis included 40 patients randomized 3:1 to the ivacaftor group (mean [SD] age, 65.3 [7.9] years; 63% male ... The researchers noted that their findings could have been affected by the single ...
Patients being treated for neovascular age-related macular degeneration (nAMD) appear to have less likelihood of submacular hemorrhage (SMH) when their most recent biologic agent was faricimab, ...